The Health Canada Special Access Program (SAP) is the federal regulatory pathway that allows a Canadian physician to request a drug that is not authorized for sale in Canada for a specific patient with a serious or life-threatening condition when conventional treatments have failed, are unsuitable, or are unavailable. For psychedelic-assisted psychotherapy, the SAP is currently the only legal access route to psilocybin and MDMA in Canada — neither substance has Health Canada approval as a therapeutic product, and both remain controlled under the Controlled Drugs and Substances Act (Schedule III psilocybin; Schedule I MDMA). Following the January 5, 2022 amendment to the Food and Drug Regulations, Health Canada formally restored the ability of practitioners to request restricted drugs (including psilocybin and MDMA) through the SAP for psychedelic-assisted psychotherapy on a case-by-case basis. This guide walks through the application process step by step, the clinical-justification requirements, the indications most and least likely to be approved in practice, the supply chain (including Filament Health's no-charge SAP psilocybin program), the Quebec RAMQ Farzin/Stephan public-funding precedent, and what to do if an application is denied.

Key takeaways

SAP is investigational, not an approved indication. A Health Canada SAP authorization is permission for a specific physician to obtain a specific drug for a specific patient — not a Health Canada endorsement that the drug works.

The January 5, 2022 amendment restored SAP eligibility for restricted drugs, including psilocybin and MDMA, for psychedelic-assisted psychotherapy. Prior to that amendment (and following 2013 changes), restricted drugs were largely excluded from the SAP.

Applications are physician-led. The patient cannot apply directly. A licensed Canadian physician submits the application via Health Canada's SAP online portal using the current SAP request form (SAP-G0006 or its current equivalent).

Health Canada review timelines are typically days to a few weeks for end-of-life distress, and longer (often several weeks) for non-end-of-life indications.

Indications most-approved in practice: end-of-life psychological distress (psilocybin), treatment-resistant depression (psilocybin), and PTSD (MDMA, case-by-case). Less-approved: substance-use disorder primary, anxiety primary, OCD primary.

Approval is not coverage. SAP authorization grants legal access; it does not pay for the drug or the clinical hours. Filament Health has supplied SAP-approved psilocybin at no charge for many Canadian patients; clinical fees remain separate.

Quebec RAMQ Farzin/Stephan December 2022 precedent is the only established Canadian provincial public-funding pathway for SAP-approved psilocybin therapy.

What the SAP is — and what it is not

The Special Access Program is administered by Health Canada's Office of Submissions and Intellectual Property (OSIP) under the Food and Drugs Act and the Food and Drug Regulations (sections C.08.010 and C.08.011). The SAP allows a practitioner to request a drug that is not marketed in Canada when:

The patient has a serious or life-threatening condition, and
Conventional therapies have failed, are unsuitable, or are unavailable, and
The practitioner can provide clinical justification that the requested drug may benefit the patient.

The SAP is not a clinical trial, a research authorization, or a Health Canada finding that the requested drug works. It is a case-by-case, patient-specific authorization. Each authorization is tied to one named physician, one named patient, one specified supplier, and a defined quantity for a defined treatment plan.

The SAP has existed for decades as a route to access investigational and unapproved drugs across many therapeutic areas (oncology, rare disease, infectious disease). What is specific to psychedelic-assisted psychotherapy is the 2022 restoration of restricted drugs to the program.

The January 5, 2022 amendment

In 2013, Health Canada amended the Food and Drug Regulations in a way that excluded most "restricted drugs" — including psilocybin, MDMA, and LSD — from the SAP. From 2013 to early 2022, the only legal pathways to those substances in Canada were clinical trials and the rare section 56(1) exemption under the Controlled Drugs and Substances Act (Health Minister exemptions; Bruce Tobin / TheraPsil-led August 2020 exemptions for end-of-life patients are the well-known precedent).

On January 5, 2022, Health Canada announced amendments to the Food and Drug Regulations and the Narcotic Control Regulations that restored SAP eligibility for restricted drugs. The announcement specifically named psychedelic-assisted psychotherapy as a clinical context the change was intended to enable, while reiterating that SAP authorization is not an endorsement of safety or efficacy.

In practice, this amendment created the current Canadian psilocybin and MDMA access pathway: physician-led SAP applications, reviewed case-by-case, for serious or life-threatening conditions where conventional therapies have failed or are unsuitable.

Step-by-step application process

The SAP application is physician-led. The patient cannot apply directly. The realistic steps for a Canadian patient and their physician are:

Step 1 — Patient and physician identify need

The conversation typically starts with a patient who has a documented serious or life-threatening condition that has not responded adequately to conventional treatment. Common contexts:

A palliative-care or oncology patient with end-of-life psychological distress (existential distress, demoralization, depression, anxiety) where standard antidepressants and psychotherapy have not provided adequate relief.
A psychiatric patient with treatment-resistant depression who has failed multiple antidepressants and may already have tried Spravato or off-label ketamine.
A patient with chronic, treatment-resistant PTSD — often a veteran, first responder, or survivor of complex trauma — for whom MDMA-assisted therapy is being considered.

The patient and physician should be aligned on the rationale before any paperwork is initiated. The physician should be willing to be the named applicant and treating physician through dosing.

Step 2 — Physician submits the SAP application

Applications are submitted through Health Canada's SAP online portal using the current request form. Historically this has been Form SAP-G0006 (or its current equivalent — Health Canada periodically updates the form). The form captures:

Patient identifiers (initials, age, sex; full name is held by the physician)
Diagnosis and clinical history
Prior treatments tried, doses, durations, and reasons for failure or unsuitability
The requested drug, dosage form, dose, and quantity
The proposed treatment plan (number of dosing sessions; preparation and integration plan)
The named supplier
Practitioner identification and signed declaration

For psilocybin and MDMA, applications also reference the proposed clinical setting — supervised dosing in a suitable clinical environment with trained therapists.

Step 3 — Required clinical justification

This is where most applications succeed or fail. Health Canada is looking for a clear narrative that establishes:

Diagnosis with documented severity — DSM-5 criteria; instruments where appropriate (e.g., MADRS, PHQ-9, CAPS-5, ESAS for palliative distress); duration; functional impairment.
Prior treatments tried, with doses, durations, and outcomes — typically multiple antidepressants from different classes for TRD; first- and second-line trauma-focused psychotherapies for PTSD; standard palliative-care interventions for end-of-life distress.
Why conventional therapies are inadequate — non-response, intolerable side effects, contraindications, or insufficient time horizon (in the end-of-life context).
Why the requested drug may benefit this patient — referencing the relevant published evidence (Goodwin 2022 NEJM COMP001 and Carhart-Harris 2021 NEJM for psilocybin in depression; Griffiths 2016 and Ross 2016 for psilocybin in cancer-related distress; Mitchell 2021 Nature Medicine MAPP1 and Mitchell 2023 MAPP2 for MDMA-AT in PTSD).
A defined treatment plan — typically one to two dosing sessions for psilocybin; three for MDMA-AT — with structured preparation and integration psychotherapy by qualified clinicians.

Comprehensive, specific, and honestly framed justifications are approved more often than thin or templated ones.

Step 4 — Health Canada review

Review timelines vary by indication and completeness:

End-of-life distress applications are often reviewed within days to two weeks. Health Canada has historically prioritized these on humanitarian grounds.
Treatment-resistant depression and other non-end-of-life indications generally take longer — often several weeks, occasionally more, particularly where additional clinical detail is requested.
MDMA-AT applications for PTSD have been reviewed case-by-case and can run multiple weeks.

Health Canada may request additional information (more detail on prior treatments, additional safety screening, or clarification of the treatment plan). Responding promptly and completely is the single biggest determinant of timely approval after the initial submission.

Step 5 — Approval letter and named supplier

A successful application produces an SAP authorization letter specifying:

The authorized practitioner
The named patient
The drug, dosage form, dose, and quantity
The named supplier from whom the drug may be obtained

The supplier is critical. The physician cannot source the drug from any source — only the supplier named in the authorization letter. For psilocybin, this is most commonly Filament Health. For MDMA, supply has historically been routed through Lykos Therapeutics (formerly MAPS PBC) or other licensed suppliers; supply has at times been constrained.

Step 6 — Treatment proceeds under approved physician supervision

Dosing occurs in a clinical setting under the named physician's supervision (often with a co-therapist team). Standard structure:

Preparation psychotherapy sessions
Dosing day(s) with monitored medication administration and supportive presence
Integration psychotherapy sessions

The physician retains responsibility for the patient's clinical care throughout. Adverse events must be reported to Health Canada per SAP requirements.

Indications most-approved in practice

Based on publicly reported SAP volumes (TheraPsil, Filament Health), the indications most-frequently approved are:

End-of-life psychological distress (psilocybin) — the strongest precedent. The 2020 section 56(1) exemption pathway and the post-2022 SAP pathway both began here. Griffiths 2016 and Ross 2016 evidence base in cancer-related distress is well-established.
Treatment-resistant depression (psilocybin) — building case base post-2022, supported by Goodwin 2022 NEJM COMP001 phase 2 evidence; MAGNUS phase 3 ongoing.
PTSD (MDMA, case-by-case) — approvals occur, particularly for veterans and first responders with complex/refractory PTSD, but supply constraints and the August 2024 FDA Complete Response Letter on Lykos's MDMA-AT application have created caution.

For deep-dive on each: End-of-Life Distress and Psychedelic-Assisted Therapy, Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy.

Indications less-approved in practice

Applications outside the established indications are more often deferred or denied:

Substance-use disorder as the primary indication — evidence base is developing (e.g., Bogenschutz 2022 alcohol use disorder), but Health Canada has been more cautious.
Anxiety disorders as the primary indication (without comorbid life-threatening illness)
Obsessive-compulsive disorder as the primary indication
Eating disorders as the primary indication
Conditions where conventional treatments have not been adequately tried

This does not mean these patients have no path — but the SAP narrative needs to be especially careful, well-evidenced, and honest about the investigational nature.

Suppliers and cost

Filament Health — no-charge SAP psilocybin

Filament Health is the principal Canadian-licensed supplier of natural psilocybin for the SAP. Filament has operated a no-charge SAP psilocybin supply program for many Canadian SAP-approved patients, materially reducing the cost burden. The drug itself is often supplied at no cost to the patient or clinic.

This is a Canadian-specific cost reduction that does not exist in many other jurisdictions and is a meaningful distinguishing feature of the Canadian SAP psilocybin pathway.

Other suppliers

Other Health Canada-licensed psilocybin suppliers exist (synthetic and natural). Compass Pathways' COMP360 has been used in Canadian clinical trials but is not currently SAP-supplied at scale.

Lykos for MDMA

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) is the principal MDMA supply chain. Supply has historically been constrained relative to demand, and the August 2024 FDA Complete Response Letter on Lykos's PTSD application has affected the regulatory and commercial landscape. SAP MDMA approvals continue but are case-by-case and supply-aware.

Cost in practice

SAP authorization grants legal access, not coverage. Cost components:

Drug: often $0 for psilocybin via Filament's program; variable for MDMA
Clinical hours: preparation + dosing + integration, typically delivered by a physician-led team with co-therapists. Out-of-pocket clinical fees in Canada have ranged ~CAD $2,500–$6,500 per program for psilocybin and ~CAD $7,500–$15,000 for MDMA-AT, depending on number of sessions and clinical intensity.
Travel and time off work are real costs to factor in.

For cost detail by substance see Psilocybin-Assisted Therapy Cost in Canada and MDMA-Assisted Therapy Cost in Canada.

Quebec RAMQ Farzin/Stephan precedent

In December 2022, Quebec's public health insurance plan (RAMQ) covered the clinical fees for SAP-approved psilocybin-assisted psychotherapy delivered by Drs. Houman Farzin and Stéphan Stephan to a Quebec patient with end-of-life distress — the first publicly funded psychedelic-assisted therapy in Canadian history. RAMQ subsequently modified billing codes to allow further claims for SAP-approved Quebec patients.

The precedent is real, capacity-limited, and dependent on physician engagement with the appropriate billing pathways. It has primarily been used for end-of-life distress in palliative-care contexts, though the framework can in principle extend to other SAP-approved indications.

For deep-dive: Quebec RAMQ Coverage for Psychedelic Therapy.

Practical tips for SAP applications

The applications that are approved most efficiently tend to share a few features:

Comprehensive prior-treatment documentation — drugs, doses, durations, outcomes, side effects, reasons for discontinuation. Generic statements ("multiple antidepressants tried") are weaker than specifics ("sertraline 200 mg × 10 weeks — partial response, GI intolerance; venlafaxine XR 225 mg × 8 weeks — non-response; etc.").
Detailed clinical justification that names the evidence and connects it to the patient — not a generic literature review.
Named supervising physician who is willing to be the SAP applicant and treating physician through dosing. SAP applications without a named, engaged physician do not move forward.
Realistic, well-defined treatment plan with preparation and integration sessions specified.
Honest framing of the investigational nature — Health Canada reviewers respond better to clear-eyed clinical reasoning than to advocacy framing.
Responsiveness to information requests during review.

TheraPsil and the SAP-pathway clinician network

TheraPsil is a Canadian non-profit that has trained clinicians in psilocybin-assisted psychotherapy and supported patients in navigating the SAP pathway. The TheraPsil-trained clinical network is concentrated in British Columbia (TheraPsil's origins are in Victoria), with growing presence in Ontario, Quebec, Alberta, and the Atlantic provinces. TheraPsil's clinical training program and patient-support resources remain a primary route for Canadian patients seeking SAP-pathway psilocybin therapy.

For SAP-pathway MDMA-AT, the trained clinician base is smaller. Canadian MAPS-trained therapists exist in major centres but capacity is more limited.

How coordinated care model can layer on top

ATMA CENA's coordinated care model is designed to integrate with patients who already have an SAP pathway underway — for example, a Canadian patient whose family physician or palliative-care physician has secured an SAP authorization for psilocybin and is seeking a clinical home for the preparation, dosing, and integration support. coordinated care is structured so that the patient's existing therapist, psychiatrist, or family physician can remain primary while ATMA CENA layers the psychedelic-specific clinical infrastructure on top.

For more detail: find care near you.

Frequent reasons for SAP denial — and what to do if denied

Common reasons applications are deferred, returned for more information, or denied:

Insufficient documentation of prior treatments — most-common single cause. Health Canada wants drugs, doses, durations, outcomes.
Conventional treatments not adequately tried — for example, an SAP psilocybin application for depression where the patient has not yet had adequate trials of two antidepressant classes.
Indication outside the established pattern — applications for primary SUD, primary OCD, or primary anxiety face higher scrutiny.
Clinical setting concerns — inadequate description of supervised dosing, qualified clinical team, or preparation/integration plan.
Supplier or supply issues — particularly for MDMA where supply has been constrained.
Unsuitable evidence framing — over-claiming benefit; insufficient acknowledgement of risks or investigational status.

If an application is denied, the physician can respond to the deficiencies identified by Health Canada — typically by providing additional clinical detail, re-framing the justification, or revising the treatment plan — and resubmit. There is no formal appeal process per se; the practical path is a strengthened resubmission. Patients who feel an application has been unfairly handled may also seek patient-advocacy support through TheraPsil or peer organizations.

What this guide does NOT promise

To be fully clear:

An SAP application is not guaranteed to be approved.
Approval is not a Health Canada finding that psilocybin or MDMA works for the patient's condition. Both substances remain investigational.
Approval is not coverage — SAP grants legal access, not payment. Canadian patients should expect out-of-pocket clinical fees in most cases.
Outcomes from SAP-pathway treatment vary patient to patient. There are no guaranteed outcomes, and this article does not promise any.
Patient and physician burden are real — applications take time, documentation, and clinical engagement.

Frequently asked questions

What is the Health Canada Special Access Program? A federal regulatory pathway, administered under sections C.08.010 and C.08.011 of the Food and Drug Regulations, that allows a Canadian physician to request a drug that is not authorized for sale in Canada for a patient with a serious or life-threatening condition where conventional therapies have failed, are unsuitable, or are unavailable.

Can a patient apply directly? No. The SAP is physician-led. A licensed Canadian physician submits the application on behalf of a specific patient.

What changed in January 2022? On January 5, 2022, Health Canada amended the Food and Drug Regulations to restore the eligibility of restricted drugs — including psilocybin and MDMA — for the SAP, specifically referencing psychedelic-assisted psychotherapy as a clinical context the change was intended to enable.

How long does Health Canada review take? End-of-life distress applications are often reviewed within days to two weeks. Non-end-of-life indications (such as treatment-resistant depression) typically take longer — often several weeks. Timelines depend on completeness and any information requests.

Is the drug supplied at no cost? Filament Health has supplied SAP-approved psilocybin at no charge for many Canadian patients via its SAP program. MDMA supply (historically through Lykos Therapeutics) is more constrained and not no-charge. Clinical fees are separate from drug cost in either case.

Does insurance cover SAP-pathway therapy? Generally no. The drug itself is essentially never covered by private insurance because it has no Health Canada approved indication. Quebec RAMQ has a public-funding precedent (Farzin/Stephan December 2022) for SAP-approved psilocybin patients. VAC may consider MDMA-AT case-by-case for service-related PTSD; VAC does not currently cover psilocybin. See Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

What if my physician has never submitted an SAP application? That is common. Health Canada provides guidance documents and the SAP online portal walks through the form. Patient-advocacy organizations (TheraPsil) and clinical networks can support physicians through their first applications. ATMA CENA's coordinated care model is designed in part to support this.

Can the same patient have multiple SAP authorizations over time? Yes — each SAP authorization is for a defined quantity and treatment plan. Subsequent applications for additional dosing or maintenance can be submitted if clinically justified.

What happens if my application is denied? The physician can respond to Health Canada's stated deficiencies — typically with additional clinical detail or a revised treatment plan — and resubmit. There is no formal appeal process; the practical path is a strengthened resubmission.

Is the SAP the same as a section 56(1) exemption? No. A section 56(1) exemption is a Health Minister exemption under the Controlled Drugs and Substances Act — the pathway used in 2020 for the first end-of-life psilocybin patients before the 2022 SAP amendment. Today, the SAP is the standard pathway; section 56(1) exemptions remain rare.

Sources

Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
Health Canada — Requests to the Special Access Program for Psychedelic-Assisted Psychotherapy (January 5, 2022 announcement): https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada — Guidance Document for Industry and Practitioners: Special Access Programme for Drugs.
Food and Drug Regulations — sections C.08.010 and C.08.011.
Filament Health — SAP psilocybin supply program: https://filament.health/
TheraPsil: https://therapsil.ca/
TheraPsil — Quebec first province to cover costs of psilocybin-assisted psychotherapy (Farzin/Stephan precedent, December 2022): https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
Lykos Therapeutics (formerly MAPS Public Benefit Corporation): https://lykospbc.com/
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12):1181-1197. PMID: 27909165.
Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12):1165-1180. PMID: 27909164.

Last updated: 2026-05-06

Health Canada Special Access Program (SAP) Application Process — A Complete Guide

Access and legality vary by jurisdiction